Date: Jan 11, 2010 Author: Thomas Lee Source: MedCity News (
click here to go to the source)
EDEN PRAIRIE, Minnesota-- Vatrix Medical Inc. is seeking $2.2 million in early stage capital, according to documents filed with the Securities and Exchange Commission.
The company, which has so far raised $230,000 from the sale of equity and options/warrants, is developing technology to prevent and treat vascular aneurysms, a fatal disease that causes the walls of blood vessels to expand, weaken and ultimately rupture.
Nancy Ness, a Vatrix executive and director, did not immediately return a phone call for comment.
Not much is known about Vatrix, founded by Matthew Ogle with help from his father Raymond, a prolific medical device entrepreneur who also serves on the Vatrix board. Matthew Ogle is also the former CEO of Lumen Biomedical Inc., a maker of a catheter that removes clots from blood vessels. He left the company after it reached a global licensing deal with Volcano Corp. last year.
According to a patent application filed last year with the U.S. Patent and Trademark Office, Vatrix is developing a diagnostic kit that can predict the risk of aneurysms in a patient by analyzing the presence of genetic biomarkers in blood and urine such as desmosine, isodesmosine and metalloproteinase. These biomarkers are linked to the degradation of elastin and collagen, proteins that provide strength, support and flexibility to tissue found in blood vessels.
Vatrix was a bioscience finalist in the 2009 Minnesota Cup, the state's annual competition for new companies. The company was also selected to present at an angel investors conference in Wisconsin last year.
Read more: http://medcitynews.com/2010/01/vatrix-medical-on-the-prowl/#ixzz2gE703h8d
